SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 21, 1998
Uroplasty, Inc.
(Exact name of registrant as specified in its charter)
Minnesota 000-20989 41-1719250
(State or other juris- (Commission File (IRS Employer
diction of incorporation) Number) Identification No.)
2718 Summer Street N.E., Minneapolis, Minnesota 55413
(Address of principal executive offices) (Zip Code)
Registrant`s telephone number, including area code: (612) 378-1180
Not applicable
(Former name or former address, if changed since last report)
Item 5. Other Events.
UROPLASTY, INC. ANNOUNCES PATENT INTERFERENCE ACTION
Tuesday, July 21, 1998
Uroplasty, Inc.("Uroplasty") Minneapolis, Minnesota, announced today that
the United States Patent and Trademark Office ("USPTO") had informed
Uroplasty that the USPTO will initiate an interference proceeding between
Uroplasty and Advanced UroScience, Inc. ("AUI"), White Bear Lake, Minn.,
to determine which company was the first to invent carbon-coated micro
beads for use in treating urinary incontinence.
Uroplasty expects that it could take the USPTO twenty-four months or more
to reach a final decision concerning this matter. Although the USPTO
originally granted the applicable patent to AUI, the interference
proceeding may result in a determination that either Uroplasty or AUI is
the proper holder, or that a patent should not have been granted.
An interference proceeding, like other patent litigation, can be complex,
time-consuming and expensive.
Uroplasty's main product is Macroplastique, an injectable, solid silicone
implant sold only outside the United States for the treatment of stress
urinary incontinence in females, vesicoureteral reflux (back flow of urine
from the bladder to the kidney) in children and incontinence in males due
to prostate surgery.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
UROPLASTY, INC.
Dated: July 21, 1998 By: /s/ Daniel G. Holman
Daniel G. Holman, President, CEO
